PhaseBio Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PHAS research report →
About the company
PhaseBio Pharmaceuticals, Inc. (PHAS) is a clinical-stage biopharmaceutical entity primarily dedicated to discovering, developing, and bringing to market innovative therapies for cardiovascular conditions. Its flagship product in development, bentracimab (PB2452), serves as a reversal agent specifically designed to counteract the effects of the antiplatelet medication ticagrelor.
- CEO
- Jonathan Mow
- IPO
- 2018
- Employees
- 60
- HQ
- Malvern, PA, US
Price Chart
- Market Cap
- $0
- P/E
- -15.58
- P/S
- 0.00
- P/B
- -0.02
- EV/EBITDA
- -20.42
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -1204.12%
- Net Margin
- -1210.15%
- ROE
- 0.22%
- ROIC
- -0.34%
- Revenue
- $10.83K · -96.62%
- Net Income
- $-131,071 · 99.87%
- EPS
- $-0.00 · 99.87%
- Op Income
- $-130,418
- FCF YoY
- 18.37%
- 52W High
- $4.08
- 52W Low
- $0.04
- 50D MA
- $0.43
- 200D MA
- $0.91
- Beta
- 2.87
- Avg Volume
- 1.79M
Get TickerSpark's AI analysis on PHAS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 19, 23 | van den Broek Richard | other | 3,750 |
| May 19, 23 | van den Broek Richard | other | 3,750 |
| May 19, 23 | Thorp Clay | other | 3,750 |
| May 19, 23 | Thorp Clay | other | 3,750 |
| May 19, 23 | Humphries William D. | other | 2,538 |
| May 19, 23 | Humphries William D. | other | 2,538 |
| May 19, 23 | HARRIGAN EDMUND | other | 3,750 |
| May 19, 23 | HARRIGAN EDMUND | other | 3,750 |
| May 19, 23 | Sapir Alex | other | 3,750 |
| May 19, 23 | Sapir Alex | other | 3,750 |
Our PHAS coverage
Recent articles, reports, and earnings notes.
No research on PHAS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PHAS report →Similar companies
Peers in the same neighborhood.